Trials / Completed
CompletedNCT03927144
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 621 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG334 | Subcutaneous Injection |
| DRUG | Oral Prophylactic | SOC Oral Tablet/Capsule |
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2021-10-01
- Completion
- 2022-09-30
- First posted
- 2019-04-25
- Last updated
- 2023-11-18
- Results posted
- 2022-10-25
Locations
112 sites across 18 countries: United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Slovakia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03927144. Inclusion in this directory is not an endorsement.